Compare iShares MBS ETF (MBB) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs BIO-TECHNE Corp — how do they compare? iShares MBS ETF trades at $93.39, while BIO-TECHNE Corp trades at $71.58 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while iShares MBS ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| MBB | TECH | |
|---|---|---|
52-Week High | $96.91 | $72.12 |
52-Week Low | $92.92 | $43.31 |
Market Cap | — | $11.16B |
Sector | — | Health |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $93.57, down 0.22% on the day, with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings and has upcoming dividend payments. Recent news highlights institutional activity, including Comerica Bank reducing its stake while Concurrent Investment Advisors and Aureum Wealth increased positions in Q4 2026.
The outlook remains cautious due to bearish technical trends and mixed institutional sentiment. Risks include interest rate sensitivity impacting mortgage-backed securities. Opportunities lie in steady dividend income, but investors should monitor Federal Reserve policy shifts for potential volatility in the MBS market.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
